PPT Slide

Protect 1- Protect 2 Change: Oral heparin administered after recovery from residual anesthetic and pain medications instead of immediately following surgery in the post operative period
Clinicians to dose one of the two approved LMWHs in the U.S. (Aventis’ Lovenox or Pharmacia’s Fragmin)
Patients will be randomized to either 12 or 18 mls of oral heparin 3xs daily for 27 days or to injectable Lovenox, 2xs daily for 7 days
Double-blinded, double dummy
Expected enrollment = (to be determined with unblinding of data from PROTECT-1)
Like PROTECT-1, a multi-center study planned for sites in U.S., Russia, Poland, Spain and Ukraine
Using high enrolling sites from PROTECT-1